October 3, 2013 — At RSNA 2013, GE Healthcare will showcase a range of molecular imaging tools designed to enable treatment evaluation earlier in a patient’s care pathway. Q.Suite, a collection of capabilities designed to extend quantitative positron emission tomography (PET) by generating more consistent standardized uptake value (SUV) readings, enabling clinicians to assess treatment response. Q.Suite is designed to help improve consistency of quantitative measurements in every key area: daily quality control, scanner workflow, motion correction, reconstruction algorithms and analysis and reporting applications. Controlling these variables to increase consistency can improve the clinician’s confidence that an SUV change has useful clinical meaning.

GE Healthcare’s latest Xeleris Processing and Review workstation software enables automation, personalization, access and advanced applications. Nuclear medicine clinicians will gain access to specific image results where and when they are needed using Xeleris. The availability of Xeleris applications extends not only to GE Centricity PACS systems and Xeleris Floating clients (XFL), but now includes an open application for virtually any picture archiving and communication system (PACS) and the GE AW Server workstation environment.

For more information: www.gehealthcare.com


Additional Content

News | SNMMI

The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...

Time April 07, 2026
arrow
News | PET Imaging

March 25, 2026 — Catalyst MedTech, a provider of nuclear medicine and molecular imaging solutions, has announced it is ...

Time April 06, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
Subscribe Now